GAINESVILLE, Fla. -- Exactech, Inc. (Nasdaq: EXAC,), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, today announced its schedule of future events.

Exactech will present to investment community analysts on February 24 at the Canaccord Adams Musculoskeletal Conference to be held at the University of Nevada, Las Vegas. Exactech President David Petty will deliver his presentation at 3:00 p.m. PST, which will also be available via audio webcast at http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2550240.

The company will then host financial analyst meetings in conjunction with the company’s exhibit for surgeons during the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in Las Vegas February 25 – 27, 2009.

During the AAOS annual meeting, Exactech will demonstrate its latest products to the orthopaedic surgical community. Financial analysts are also invited to the company’s exhibit to view prosthetic products and meet with company representatives.

Exactech will be highlighting its new Novation® Element™ tapered-wedge hip stem system. The geometry of this stem facilitates insertion using traditional and smaller incisions with varied surgical approaches, and the system offers specialized instrumentation to specifically support the anterior approach to the hip.

Also to be featured will be the Optetrak® CR Slope™, a patent-pending design that enables surgeons to plan and perform PCL-retaining total knee arthroplasty based on maintaining the anatomical integrity of the posterior cruciate ligament.

Surgeons and other technical experts will be available to discuss design rationales and clinical outcomes associated with Exactech products.

About the AAOS
Founded in 1933, The American Academy of Orthopaedic Surgeons is the preeminent provider of musculoskeletal education to orthopaedic surgeons and others in the world. Its continuing medical education activities include a world-renowned annual meeting, multiple CME courses held around the country and at the Orthopaedic Learning Center, and various medical and scientific publications and electronic media materials. http://www.aaos.org/education/anmeet/anmeet.asp.

About Exactech
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States and Australia, in addition to more than 30 markets in Europe, Asia and Latin America. Additional information about Exactech, Inc. can be found at www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at www.exac.com and www.hawkassociates.com.

An investment profile on Exactech may be found at www.hawkassociates.com/profile/exac.cfm.

Investors may contact Chief Financial Officer Jody Phillips at 352-377-1140 or Julie Marshall or Frank Hawkins, Hawk Associates Inc., at 305-451-1888, e-mail: exactech@hawkassociates.com. To receive future releases in e-mail alerts, sign up at www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

PDF